ProMetic Life Sciences Inc. announced that it has amended its licensing agreement originally entered into with Hematech BioTherapeutics Inc. in May 2012. ProMetic has reacquired the rights initially granted to Hematech in the License Agreement, to a 50% share of the worldwide profits related to plasminogen congenital deficiency sales. The parties had originally entered into two separate agreements: the Licensing Agreement and a further agreement which provided Hematech with the manufacturing rights to supply ProMetic with additional plasma-derived biopharmaceuticals on a contract manufacturing basis (the "CMO relationship"). Since 2012, ProMetic has secured the required cGMP manufacturing capacity to allow for the achievement of its ambitious corporate goals. As a consequence of the positive steps taken by ProMetic to secure such capacity, the pace at which the Taiwanese manufacturing capacity needs to be brought on line has become less critical. However, this CMO relationship between ProMetic and Hematech is maintained for future manufacturing capacity expansion and the parties will continue to work together on this project.